{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:42:45Z","timestamp":1792028565325,"version":"4.4.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute of Health"},{"DOI":"10.13039\/100007313","name":"MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1093\/annonc\/mdy173","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T19:10:16Z","timestamp":1525806616000},"page":"1880-1882","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor"],"prefix":"10.1016","volume":"29","author":[{"given":"S.","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Manshouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Asatiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy173_bb0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy173_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1093\/annonc\/mdy173_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdy173_bb0025","doi-asserted-by":"crossref","unstructured":"PCCWL Liu, H Koblish, L Wu et al. Preclinical characterization of the selective FGFR inhibitor INCB054828. Proceedings of AACR 106th Annual Meeting 2015, 18\u201322 April 2015; Philadelphia, PA, abstract nr 771.","DOI":"10.1158\/1538-7445.AM2015-771"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdy173_bb0030","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/j.clml.2017.07.176","article-title":"Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid\/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement","volume":"17","author":"Verstovsek","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1880\/31190856\/mdy173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1880\/31190856\/mdy173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T21:46:20Z","timestamp":1631828780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419341079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0923753419341079"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy173","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}